Equity Profile

MRNA

Moderna, Inc.

Health CareBiotechnology$18.3B

Jul31Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics. With a market cap of $18 billion, it plays a crucial role in the health care sector, especially in response to infectious diseases and other medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing estimates by 12.58%. The stock reacted negatively, dropping 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of beating EPS estimates but has struggled with revenue guidance. Investors are keenly watching for any signs of recovery in vaccine sales.

Bull Case

If Moderna can demonstrate strong vaccine sales and improved cost management, it could lead to a significant rebound in stock price.

Bear Case

Conversely, if the company continues to miss EPS estimates and revenue expectations, it could further erode investor confidence and lead to a deeper decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the current sales figures for COVID-19 vaccines?

Given the ongoing demand for vaccines, this number will be crucial for assessing the company's revenue health.

What is the outlook for new product developments?

Insights into future products could indicate growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in vaccine sales due to ongoing public health needs, which could lead to stronger-than-expected revenue.

Supporting Evidence

Options are pricing a 16.5% move, indicating high volatility expectations not reflected in historical performance.

The company's recent history shows a 75% EPS beat rate, suggesting a potential for positive surprises.

Key Risk

If vaccine sales exceed $1 billion, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the sustainability of vaccine demand and the company's ability to innovate beyond COVID-19.

Bull Confirmed If

A significant improvement in vaccine sales, exceeding $1 billion, would confirm the bull case.

Bear Confirmed If

If vaccine sales drop below $500 million, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats expectations, history suggests a potential stock increase of around 4.55%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.

Miss

A miss could lead to a decline of about 1.06%, reinforcing negative sentiment in the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and demand trends.
2Any new product announcements or pipeline developments.
3Management's outlook on future revenue streams.
4Details on cost management strategies.
5Responses to market competition and pricing pressures.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul28

KNSABMO

Kiniksa Pharmaceuticals International, plc

PreviewView

Jul28

CURBBMO

Company Snapshot

Moderna, Inc. is a biotechnology company focused on developing mRNA-based vaccines and therapeutics....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing costs and generating revenue.

N/A

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

MRNA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+27.75%

Avg Stock Reaction

-3.15%

Last Quarter Recap

In Q1 2026, Moderna reported an EPS of -$3.40, missing estimates by 12.58%. The stock reacted negatively, dropping 1.24% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Moderna can demonstrate strong vaccine sales and improved cost management, it could lead to a significant rebound in stock price.

Bear Case

Conversely, if the company continues to miss EPS estimates and revenue expectations, it could further erode investor confidence and lead to a deeper decline in stock value.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the current sales figures for COVID-19 vaccines?

Given the ongoing demand for vaccines, this number will be crucial for assessing the company's revenue health.

What is the outlook for new product developments?

Insights into future products could indicate growth potential and market positioning.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a rebound in vaccine sales due to ongoing public health needs, which could lead to stronger-than-expected revenue.

Supporting Evidence

Options are pricing a 16.5% move, indicating high volatility expectations not reflected in historical performance.

The company's recent history shows a 75% EPS beat rate, suggesting a potential for positive surprises.

Key Risk

If vaccine sales exceed $1 billion, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the sustainability of vaccine demand and the company's ability to innovate beyond COVID-19.

Bull Confirmed If

A significant improvement in vaccine sales, exceeding $1 billion, would confirm the bull case.

Bear Confirmed If

If vaccine sales drop below $500 million, it would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±16.5%

Historical Avg

±6.1%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±16.5% while MRNA has averaged ±6.1% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

55.7%

Calls (790K)P/C Ratio: 0.12Puts (624K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Moderna beats expectations, history suggests a potential stock increase of around 4.55%, confirming a positive outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience a muted reaction, reflecting uncertainty.

Miss

A miss could lead to a decline of about 1.06%, reinforcing negative sentiment in the market.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on vaccine sales and demand trends.
2Any new product announcements or pipeline developments.
3Management's outlook on future revenue streams.
4Details on cost management strategies.
5Responses to market competition and pricing pressures.